GCM
RXST icon

Ghisallo Capital Management’s RxSight RXST Stock Holding History

Ghisallo Capital Management’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,000
Closed -$113K – 386
2021
Q4 		$113K Hold
10,000
– – 0.01% 443
2021
Q3 		$127K Buy
+10,000
New +$138K ﹤0.01% 445

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Ghisallo Capital Management's RXST Position: Q1 2022 in Review

Ghisallo Capital Management sold out of RxSight (RXST) in Q1 2022, closing a stake of 10,000 shares — an estimated $113K sold.

Ghisallo Capital Management first reported a position in RXST in Q3 2021 and held it in 2 quarters. The position peaked at $127K in Q3 2021. 45 funds tracked by Wall St. Rank hold RXST as of Q1 2022.

  • Ghisallo Capital Management reported no remaining RxSight position as of Q1 2022 after selling out during the quarter.
  • Ghisallo Capital Management sold 10,000 RxSight shares in Q1 2022, an estimated $113K.
  • Ghisallo Capital Management first reported a position in RxSight in Q3 2021 and held it in 2 quarters.
  • Ghisallo Capital Management's RxSight position peaked at $127K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held RxSight as of Q1 2022.

Based on Ghisallo Capital Management's 13F filing for Q1 2022, filed 10 May 2022.